GERRESHEIMER AG (GXI.DE) Stock Fundamental Analysis
Europe - FRA:GXI - DE000A0LD6E6 - Common Stock
37.72 EUR
-0.26 (-0.68%)
GXI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. GXI has a bad profitability rating. Also its financial health evaluation is rather negative. GXI has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
GXI had positive earnings in the past year.
In the past year GXI had a positive cash flow from operations.
In the past 5 years GXI has always been profitable.
GXI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
GXI has a worse Return On Assets (1.33%) than 70.00% of its industry peers.
GXI has a Return On Equity of 4.39%. This is in the lower half of the industry: GXI underperforms 70.00% of its industry peers.
GXI has a worse Return On Invested Capital (3.59%) than 75.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GXI is in line with the industry average of 7.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.33% | ||
| ROE | 4.39% | ||
| ROIC | 3.59% |
ROA(3y)3.04%
ROA(5y)3.09%
ROE(3y)7.67%
ROE(5y)8.3%
ROIC(3y)6.14%
ROIC(5y)6.08%
1.3 Margins
The Profit Margin of GXI (2.89%) is worse than 80.00% of its industry peers.
GXI's Profit Margin has been stable in the last couple of years.
GXI has a worse Operating Margin (8.03%) than 70.00% of its industry peers.
GXI's Operating Margin has improved in the last couple of years.
GXI has a Gross Margin of 28.07%. This is in the lower half of the industry: GXI underperforms 70.00% of its industry peers.
In the last couple of years the Gross Margin of GXI has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.03% | ||
| PM (TTM) | 2.89% | ||
| GM | 28.07% |
OM growth 3Y-0.21%
OM growth 5Y2.69%
PM growth 3Y-1.23%
PM growth 5Y-1.47%
GM growth 3Y0.37%
GM growth 5Y1.38%
2. Health
2.1 Basic Checks
GXI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GXI has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for GXI has been increased compared to 5 years ago.
Compared to 1 year ago, GXI has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.04, we must say that GXI is in the distress zone and has some risk of bankruptcy.
GXI has a worse Altman-Z score (1.04) than 80.00% of its industry peers.
A Debt/Equity ratio of 1.18 is on the high side and indicates that GXI has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.18, GXI is doing worse than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.04 |
ROIC/WACC0.47
WACC7.65%
2.3 Liquidity
A Current Ratio of 1.01 indicates that GXI should not have too much problems paying its short term obligations.
The Current ratio of GXI (1.01) is worse than 85.00% of its industry peers.
A Quick Ratio of 0.56 indicates that GXI may have some problems paying its short term obligations.
GXI has a Quick ratio of 0.56. This is amonst the worse of the industry: GXI underperforms 90.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.56 |
3. Growth
3.1 Past
GXI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
Measured over the past years, GXI shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.23% on average per year.
GXI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.32%.
GXI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.90% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y4.26%
EPS 5Y-8.23%
EPS Q2Q%-27.42%
Revenue 1Y (TTM)9.32%
Revenue growth 3Y10.77%
Revenue growth 5Y7.9%
Sales Q2Q%19.57%
3.2 Future
GXI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.98% yearly.
The Revenue is expected to grow by 8.51% on average over the next years. This is quite good.
EPS Next Y-18.32%
EPS Next 2Y1.28%
EPS Next 3Y7.45%
EPS Next 5Y8.98%
Revenue Next Year17.05%
Revenue Next 2Y11.28%
Revenue Next 3Y9.65%
Revenue Next 5Y8.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.09 indicates a reasonable valuation of GXI.
GXI's Price/Earnings ratio is rather cheap when compared to the industry. GXI is cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of GXI to the average of the S&P500 Index (27.90), we can say GXI is valued rather cheaply.
A Price/Forward Earnings ratio of 7.86 indicates a rather cheap valuation of GXI.
100.00% of the companies in the same industry are more expensive than GXI, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of GXI to the average of the S&P500 Index (23.36), we can say GXI is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.09 | ||
| Fwd PE | 7.86 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GXI indicates a rather cheap valuation: GXI is cheaper than 95.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.97 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.28%
EPS Next 3Y7.45%
5. Dividend
5.1 Amount
With a yearly dividend of 0.11%, GXI is not a good candidate for dividend investing.
In the last 3 months the price of GXI has falen by -22.52%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 0.71, GXI is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.44, GXI's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.11% |
5.2 History
The dividend of GXI has a limited annual growth rate of 0.94%.
Dividend Growth(5Y)0.94%
Div Incr Years0
Div Non Decr Years6
5.3 Sustainability
69.83% of the earnings are spent on dividend by GXI. This is not a sustainable payout ratio.
The dividend of GXI is growing, but earnings are growing more, so the dividend growth is sustainable.
DP69.83%
EPS Next 2Y1.28%
EPS Next 3Y7.45%
FRA:GXI (10/7/2025, 10:04:40 AM)
37.72
-0.26 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.48%
Inst Owner ChangeN/A
Ins Owners4.92%
Ins Owner ChangeN/A
Market Cap1.30B
Analysts72.17
Price Target62.12 (64.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.11% |
Yearly Dividend1.32
Dividend Growth(5Y)0.94%
DP69.83%
Div Incr Years0
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.55%
Min EPS beat(2)-6.69%
Max EPS beat(2)17.79%
EPS beat(4)2
Avg EPS beat(4)6.98%
Min EPS beat(4)-6.69%
Max EPS beat(4)18.84%
EPS beat(8)4
Avg EPS beat(8)3.56%
EPS beat(12)7
Avg EPS beat(12)3.1%
EPS beat(16)8
Avg EPS beat(16)1.87%
Revenue beat(2)0
Avg Revenue beat(2)-1.22%
Min Revenue beat(2)-1.59%
Max Revenue beat(2)-0.85%
Revenue beat(4)0
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.59%
Max Revenue beat(4)-0.72%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)4
Avg Revenue beat(12)-0.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.15%
PT rev (1m)-5.92%
PT rev (3m)-17.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.93%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)-27.45%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)-3.65%
Revenue NY rev (1m)-0.74%
Revenue NY rev (3m)-3.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.09 | ||
| Fwd PE | 7.86 | ||
| P/S | 0.6 | ||
| P/FCF | N/A | ||
| P/OCF | 5.44 | ||
| P/B | 0.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.97 |
EPS(TTM)4.15
EY11%
EPS(NY)4.8
Fwd EY12.73%
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)6.93
OCFY18.37%
SpS63.35
BVpS41.69
TBVpS-8.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.33% | ||
| ROE | 4.39% | ||
| ROCE | 4.85% | ||
| ROIC | 3.59% | ||
| ROICexc | 3.81% | ||
| ROICexgc | 7.75% | ||
| OM | 8.03% | ||
| PM (TTM) | 2.89% | ||
| GM | 28.07% | ||
| FCFM | N/A |
ROA(3y)3.04%
ROA(5y)3.09%
ROE(3y)7.67%
ROE(5y)8.3%
ROIC(3y)6.14%
ROIC(5y)6.08%
ROICexc(3y)6.5%
ROICexc(5y)6.42%
ROICexgc(3y)14.47%
ROICexgc(5y)16.32%
ROCE(3y)8.29%
ROCE(5y)8.2%
ROICexcg growth 3Y-17.1%
ROICexcg growth 5Y-18.13%
ROICexc growth 3Y-1.3%
ROICexc growth 5Y1.06%
OM growth 3Y-0.21%
OM growth 5Y2.69%
PM growth 3Y-1.23%
PM growth 5Y-1.47%
GM growth 3Y0.37%
GM growth 5Y1.38%
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.13 | ||
| Cap/Depr | 149.83% | ||
| Cap/Sales | 16.21% | ||
| Interest Coverage | 2.39 | ||
| Cash Conversion | 58.03% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.56 | ||
| Altman-Z | 1.04 |
F-Score4
WACC7.65%
ROIC/WACC0.47
Cap/Depr(3y)167.14%
Cap/Depr(5y)152.09%
Cap/Sales(3y)15.92%
Cap/Sales(5y)14.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y4.26%
EPS 5Y-8.23%
EPS Q2Q%-27.42%
EPS Next Y-18.32%
EPS Next 2Y1.28%
EPS Next 3Y7.45%
EPS Next 5Y8.98%
Revenue 1Y (TTM)9.32%
Revenue growth 3Y10.77%
Revenue growth 5Y7.9%
Sales Q2Q%19.57%
Revenue Next Year17.05%
Revenue Next 2Y11.28%
Revenue Next 3Y9.65%
Revenue Next 5Y8.51%
EBIT growth 1Y-16.38%
EBIT growth 3Y10.54%
EBIT growth 5Y10.8%
EBIT Next Year113.62%
EBIT Next 3Y38.46%
EBIT Next 5Y24.57%
FCF growth 1Y-73.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.98%
OCF growth 3Y4.26%
OCF growth 5Y4.49%